October 16, 2026

Korea approves Boehringer’s Jascayd for idiopathic pulmonary fibrosis – Korea Biomedical Review

October 14, 2026

Bristol Myers Squibb Announces Topline Phase 3 Results for Investigational Idiopathic Pulmonary Fibrosis Treatment – Oncodaily

October 13, 2026

MAXPIRe failure ends Syndax’s axatilimab program in idiopathic pulmonary fibrosis – AllSci

October 13, 2026

Calluna Pharma Completes Dosing in Phase 2 AURORA Study of CAL101 in Idiopathic Pulmonary Fibrosis and Reports Completion of Final Independent Safety Review – Business Wire

October 12, 2026

BMS eyes filings for idiopathic pulmonary fibrosis drug – pharmaphorum